The actual and global assessment of cardiac risk forms an important step in the prevention and management of coronary heart disease (CHD).1-3 The importance of accurately identifying the risk for cardiac disease can be emphasized by the fact that patients without clinically evident CHD may be at a similar or even higher risk of experiencing a cardiovascular event compared to individuals with a previous history of myocardial infarction (MI).
Several factors that increase the risk of coronary heart disease have been identified and studied extensively.
| Non-modifiable | Modifiable |
|---|---|
| Gender: Higher in men than premenopausal women |
Active and passive smoking |
| Age: Male > 45 years Female > 55 years |
Low physical activity and obesity |
| Family History: CHD in close relatives and/or premature CHD |
Diabetes mellitus and hypertension |
| Ethnicity and Race: African Americans, Hispanic Americans, Japanese and Chinese are more prone to suffer stroke |
Unhealthy diet: Increased intake of saturated fats |
The need for timely and precise identification of patients at high risk for CHD has led to the development of various risk assessment tools. A patient’s risk for cardiac disease can be assessed using the following algorithms:
| Risk Factors | PROCAM6 | Framingham4 |
|---|---|---|
| Age and gender | X | X |
| Total cholesterol | X | |
| HDL-C | X | X |
| LDL-C | X | |
| Triglycerides | X | |
| Smoking | X | X |
| Systolic blood pressure | X | X |
| Diabetes | X | X |
| Family history of coronary heart disease | X |
Apart from the conventional established risk factors, a large number of non-classical factors have been recognized in recent years that are associated with an enhanced risk of coronary events.2
| Emerging Risk Factor Panel5 | Extended Risk Factor Panel |
|---|---|
| hsCRP | Apolipoprotein A-1 |
| Homocysteine | Apolipoprotein B |
| Lipoprotein (a) | Apo B / Apo A-1 ratio |
| Genetic markers | Cystatin C |
| Increased coronary calcium score | BNP or NT-proBNP |
| Albumin in urine |
Risk assessment using cardiac biomarkers focuses on the identification of four major pathological conditions.
As a recognized worldwide leader in CVD testing, Siemens Healthcare Diagnostics provides a comprehensive and expanding menu of cardiac biomarkers across a broad spectrum of instrument solutions that help identify patients at risk for cardiovascular disease.
Click here for our menu of risk assessment cardiac biomarkers.
Click here to learn more about our complete menu of cardiac biomarkers.
References:
1. World Health Organization. Fact sheet No 317. Feb 2007
View source. Accessed Dec 2008.
2. International Task Force for Prevention of Coronary Heart Disease / International Atherosclerosis Society. Pocket guide to prevention of coronary heart disease.
View source. Accessed Dec 2008.
3. De Backer, et al. Eur Heart J. 2003;24:1601-10.
View source.
4. American Heart Association. Heart Attack/Coronary Heart Disease Risk Assessment.
View source. Accessed December 2008.
5. Assmann G, et al. Nutr Metab Cardiovasc Dis. 2005;15:373-81.
View source.
6. Cullen P, et al. Circulation. 1997;96:2128-2136.
View source.